Neutralizing Antibody Cocktail Approach: Insights from Combination Therapy of Casirivimab and Imdevimab

The combination of Casirivimab and Imdevimab as a neutralizing antibody cocktail therapy has demonstrated significant effectiveness in treating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during the COVID-19 pandemic. By targeting distinct epitopes on the viruss spike protein, this therapy efficiently blocks viral entry into human cells and reduces the likelihood of immune escape, offering a robust defense against SARS-CoV-2. This review explores the underlying mechanisms of action, summarizing clinical outcomes that highlight the therapys efficacy in reducing severe disease, hospitalization rates, and mortality. Additionally, the review addresses the safety profile and potential adverse events associated with the Casirivimab-Imdevimab cocktail, as well as current limitations such as evolving viral variants that may affect effectiveness and the challenges of large-scale production, cold-chain storage, and distribution logistics. Insights into the future of antibody cocktail therapies are discussed, emphasizing the necessity for innovative solutions to overcome these hurdles. Continued research is essential to refine antibody therapies, ensuring accessibility and sustained efficacy in combating emerging viral threats and optimizing the global COVID-19 response.